
Browsing restrictions can be lifted for a fee.
As of Q4'25, Pfizer's EV/Sales ratio stands at 8.06, marking the lowest point in the observed period from Q1'23 to Q4'25. This latest data point reflects a significant decline from the previous quarter's value of 11.92. Over the period from Q1'23 to Q4'25, the EV/Sales ratio for Pfizer has demonstrated considerable volatility, peaking at 20.82 in Q2'23 before trending downward. Notable inflection points include sharp drops after Q2'23 and again from Q2'25 to Q4'25, indicating a consistent downward trend in valuation relative to sales, especially in the latter half of the period.